Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab vs standard of care in relapsed small cell lung cancer
NCT05740566Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2023
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 31
01
Overview
A Phase 3 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started May 2023; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05740566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740566.